Lymphovascular invasion is a high risk factor for stage I/II colorectal cancer: a systematic review and meta-analysis
Autor: | Xinye Hu, Jian-Bo Xu, Shiliang Tu, Hang Yuan, Quanjin Dong, Bo’an Zheng |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: |
Oncology
medicine.medical_specialty Lymphovascular invasion Colorectal cancer lymphovascular invasion Subgroup analysis colorectal cancer survival 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine medicine Humans Neoplasm Invasiveness Risk factor Neoplasm Metastasis Neoplasm Staging Proportional Hazards Models Proportional hazards model business.industry Hazard ratio medicine.disease Prognosis Confidence interval meta-analysis 030220 oncology & carcinogenesis Meta-analysis 030211 gastroenterology & hepatology Clinical Research Paper business stage I/II Colorectal Neoplasms Publication Bias |
Zdroj: | Oncotarget |
ISSN: | 1949-2553 |
Popis: | // Hang Yuan 1,2,* , Quanjin Dong 1,* , Bo’an Zheng 1 , Xinye Hu 1 , Jian-Bo Xu 3 and Shiliang Tu 1 1 The Surgical Department of Coloproctology, Zhejiang Provincial People’s Hospital, Hangzhou, China 2 Nanjing Medical University, Nanjing, China 3 Department of Hepatobiliary Surgery, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an City, China * These authors have contributed equally to this work Correspondence to: Jian-Bo Xu, email: // Shiliang Tu, email: // Keywords : lymphovascular invasion, survival, stage I/II, colorectal cancer, meta-analysis Received : January 04, 2017 Accepted : February 08, 2017 Published : February 16, 2017 Abstract The prognostic value of lymphovascular invasion (LVI) in stage I/II colorectal cancer (CRC) does not reach a consensus. To systematically assess prognostic significance of LVI, databases of PubMed, Web of Science, and Embase were searched from inception up to 10 Dec 2016. The pooled hazard ratio (HR) and 95% confidence intervals (CI) were used to determine the prognostic effects. Nineteen relevant studies including 9881 total patients were enrolled. Our results showed that LVI is significantly associated with poor prognosis in overall survival (OS) (HR=2.15, 95 % CI=1.72–2.68, P < 0.01) and disease-free survival (DFS) (HR=1.73, 95% CI=1.50–1.99, P < 0.01), which is similar in stage II patients. Further subgroup analysis revealed that the significance of the association between LVI and worse prognosis in CRC patients is not affected by below factors, including geographic setting, LVI positive rate, treatment, tumor site, and quality of the study. The current meta-analysis suggests that LVI may be a poor prognostic factor for stage I/II CRC patients. |
Databáze: | OpenAIRE |
Externí odkaz: |